Pictet - Biotech-P EUR

Performance (in EUR)

Past performance is no indication of current or future performance. These performance data do not take account of the commissions and costs incurred on the issue and redemption of units.

Performance

1 month 12.18%
Current year 20.65%
3 years p.a. 10.27%
5 years p.a. 5.64%
10 years p.a. 4.37%
Since inception p.a. n.a.

Rolling performance in %

Key figures

YTD 1 year 3 years 5 years 10 years
Performance 20.65% 14.43% 34.10% 31.56% 53.43%
Maximum profit on monthly basis 12.22% 12.22% 16.89% 16.89% 18.50%
Maximum loss on monthly basis -10.54% -10.54% -11.65% -17.41% -23.67%
Max drawdown -32.05% -36.31% -36.31% -37.42% -37.42%
Volatility 28.46% 28.59% 23.48% 25.15% 25.30%
Sharpe ratio 0.85 0.42 0.30 0.15 0.15
Maximum continuous profit in months 4 4 4 5 5
Maximum continuous loss in months 4 4 4 4 4
Positive months / profit duration in months 6 8 20 31 60
Negative months / loss duration in months 4 5 17 30 61

Master data

Fund name Pictet - Biotech-P EUR
Fund management company Pictet Asset Management (Europe) S.A.
Fund domicile Luxembourg
Inception date 14 June 2006
ISIN LU0255977455
Swiss security no. 2564944
Fund currency EUR
Appropriation of income accumulating
Issuing commission
Ongoing charges under PRIIP KID as at 07 February 2025 1.99%
End of financial year 30 September
Paying agent
Fund volume as at 30 September 2025 1.27 Mrd. EUR
Net asset value (NAV) as at 30 October 2025 1 027.51 EUR

Portfolio structure

Top holdings of fund volume (in %)

United Therapeutics 4.34%
Insmed 4.26%
Argenx SE (spADR) 4.00%
!Regeneron Pharmaceuticals Inc. 3.21%
Alnylam Pharma 3.17%
Neurocrine Bio 3.14%
Madrigal Pharmaceuticals Inc 3.02%
Biogen 2.71%
PTC THERAPEUTICS INC 2.57%
Gilead Sciences 2.54%

Asset allocation

Currency

Countries

Sectors